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Acute promyelocytic leukemia (APL) represents a biologic and clinically well-defined subtype of acute
nonlymphocytic leukemia with specific morphologic and karyotypic characteristics. Although secondary
leukemia and myelodysplastic syndromes (MDS) are the most frequent secondary neoplasms following
chemotherapy for acute leukemia, their development after complete remission in patients with APL is un-





 retinoid acid treatment and subsequently developed a MDS. Therapy-related





 alteration was detected in one case, possible implications of these findings in the on-
 




Secondary myelodysplastic syndrome (MDS) may result
from the exposure to DNA-damaging drugs such as alkylat-
ing agents or those targeting DNA topoisomerase II. Each
of these drug groups may induce secondary malignancies
showing various characteristics in terms of morphology, la-
tency period and cytogenetic abnormalities [1–3]. Although
these drugs are included in several acute promyelocytic leu-
kemia (APL) treatment regimens, secondary MDS develop-
ing in APL patients in complete remission (CR) are rare [4].
We describe the clinical and genetic features, emphasizing











A 70-year-old male was admitted due to asymptomatic
pancytopenia. Blood count showed Hb 8.4 g/dL, white








/L with 40% abnormal promyelo-








/L. Bone marrow aspira-
tion was hypercellular and showed 95% abnormal promyelo-
cytes. G-banding analysis revealed two clones: 46,XY,t(15;17)
(q21;q11) in 19 of 58 metaphases and 46,XY,inv(6)(p24q13),
t(15;17)(q21;q11) in 39 of 58 metaphases.
Reverse transcriptase polymerase chain reaction (RT-PCR)





CR with clearance of both cytogenetic and molecular aberra-






























 8 days). Consolidation treatment included



























 5 days) courses that were followed by maintenance















day). Treatment was completed with persistence of CR.
However, 4 months later the patient showed Hb 8.4 g/dL,








/L with 3% blast cells, and plate-








/L. Bone marrow aspiration was hyper-
cellular, showing 12% blast cells and red-cell line hyperplasia
with multiple dyserythropoyetic changes in erythroblasts
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(megaloblastoid features, internuclear chromatin bridging,
abnormal mitosis, and lobulated nuclei). Flow cytometry of
bone marrow cells showed an intense reactivity with CD34,
CD13, CD33 and HLA-DR on blast cells. A new clone with









detected at the cytogenetic study of bone marrow in 41 of
50 metaphases. Based on hematologic, immunophenotypic,
and cytogenetic changes, the patient was diagnosed with
MDS (refractory anemia with excess blast) and he refused
any treatment other than transfusion therapy. Disease evalu-
ation after 6 months showed Hb 8.1 g/dL, white blood cell

















/L. Bone marrow aspiration disclosed 25% blast
cell infiltration with the same features showed at diagnosis of
MDS. Cytogenetic analysis confirmed the presence of mono-
somies of chromosomes Y and 7. Conditions deteriorated fur-




A 60-year-old female was admitted due to asymptomatic
pancytopenia. Blood counts at admission were as follows:








/L with 28% neutro-








/L. Peripheral blood smears
showed the presence of abnormal promyelocytes. Bone mar-
row examination was consistent with APL, and diagnosis was
confirmed by cytogenetic detection of t(15;17)(q22;q11) in





script in the molecular analysis. Morphologic, cytogenetic and
molecular CR was obtained through induction treatment con-








 40 days) and in-








 4 days). Consolidation
















 1 day, respectively) and a course








 5 days). Maintenance ther-















Bone marrow analysis performed after 20 months of





 mRNA was still negative. The bone
marrow aspiration showed a decrease in red blood cell pre-
cursors, dysplastic changes in granulocytes, and increase in
the number of megakaryocytes, having nonlobulated nuclei.





drome) and is currently asymptomatic without treatment.
 




Cytogenetic studies were done on unstimulated short-
term bone marrow cultures. G-banded karyotypes were de-
scribed according to International System for Human Cyto-




Genomic DNA was extracted following standard procedures
from EDTA-anticoagulated peripheral blood and matched bone




amplification were performed according to standard pro-
tocols [5].
Loss of heterozygosity (LOH) was tested through the
analysis of the following variable number of tandem repeat





) gene and RB1.2 (D13S153), a di-





(13q14.1) and P53IVS1, a dinucleotide repeat marker located




 gene (17p13.1). In all of these cases,
the analysis consisted in a PCR amplification with specific




P-end-labeled primer and subsequent analysis
of the alleles in either 6% polyacrylamide (29:1, acrylamide:




 45-cm gels or in 7% po-
liacrylamide Spreadex Polymer NAB gels (Elchrom Scien-
tific AG, Cham, Switzerland).









 gene were per-
formed as previously described [6].
 
4. Results and discussion
 
Development of MDS after treatment for APL is rare [4].
Chemotherapy could contribute to it by several mecha-
nisms. Our patients were exposed to topoisomerase II tar-
geting agents, such as anthracyclines and mitoxantrone, but
they did not show the typical chromosomal abnormalities at
11q23 or 21q22 associated with these secondary neoplasms.
However, although they did not receive alkylating agents,
their secondary cytogenetic abnormalities included losses at
chromosomes 5 and 7, that is, aberrations often described in
patients with MDS associated with exposure to alkylating
agents. The explanation for this could be that methotrexate,
6-mercaptopurine or ATRA might modify anthracycline
leukemogenesis [4].
Aside from proven effect of chemotherapy and ionizing
radiation on development of secondary malignancies, some
authors have suggested the contribution of a genetic predis-
position to the onset of secondary MDS [2]. Studies per-
formed on patients with secondary acute leukemias have




 gene [7,8]. Since treatment with cytotoxic agents act-




-dependent apoptotic cell death program
seems to be the main risk factor for development of second-
ary leukemia, it has been hypothesized that mutations in
DNA repair genes can lead to DNA instability, thus predis-
























DNA samples from bone marrow and peripheral blood
were available for case 1, both at the moment of PML diag-
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 in these samples showed an altered DGGE
band pattern affecting the exon 7 of the gene in the MDS,
but not in samples from the PML at diagnosis (Fig. 1). Se-
quencing of the PCR products revealed a G to A transition




TAT) that changes the residue num-
ber 238 of the protein from cysteine into tyrosine (C238T).




 gene did not show LOH at this locus. In fact, the elec-
trophoretogram of the sequencing of the blood sample
showed the presence of the peaks corresponding to the nor-
mal (guanine) and mutant (adenine) strands with the same
intensity, whereas in the bone marrow there was a clear
overrepresentation of the mutant allele (Fig. 2). The pres-
ence of normal, non-leukemic cells in the bone marrow (re-
sidual normal hematopoiesis) and the peripheral blood of
the patient, makes the analysis of LOH by comparison of
the alleles for the P53IVS1 marker useless in this case. With




 gene that we performed in this study we cannot rule
out the presence of alteration in the other allele outside this
region.
This mutation has been frequently described in a wide vari-
ety of human tumors, including hematologic malignancies.
Nevertheless, to our knowledge, it has never been described









 deletion has been




 function and a putative tumor suppressor gene at 5q, we









 (case 2). Because alterations on 13q14 have been
found in a subgroup of acute leukemias resulting from MDS
transformation and occasionally in therapy-related acute









genes. These genes act as nega-
tive regulators of cell proliferation by blocking cell-cycle
transition from G1 into S phase through their protein prod-
ucts. Nevertheless, no abnormalities were detected at these
genes in the samples from our patients.
In conclusion, we describe two new cases of MDS after





tion in both the bone marrow and blood samples at MDS de-
velopment in one of the cases, but not at PML diagnosis,
suggests that the pattern of molecular alterations changes
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